GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PureTech Health PLC (NAS:PRTC) » Definitions » Effective Interest Rate on Debt %

PureTech Health (PureTech Health) Effective Interest Rate on Debt % : 66.77% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is PureTech Health Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. PureTech Health's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was $17.00 Mil. PureTech Health's average total debt for the quarter that ended in Dec. 2023 was $25.46 Mil. Therefore, PureTech Health's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 66.77%.


PureTech Health Effective Interest Rate on Debt % Historical Data

The historical data trend for PureTech Health's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PureTech Health Effective Interest Rate on Debt % Chart

PureTech Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.24 5.08 7.29 7.94 37.36

PureTech Health Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.15 7.78 8.39 27.54 66.77

Competitive Comparison of PureTech Health's Effective Interest Rate on Debt %

For the Biotechnology subindustry, PureTech Health's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PureTech Health's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PureTech Health's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where PureTech Health's Effective Interest Rate on Debt % falls into.



PureTech Health Effective Interest Rate on Debt % Calculation

PureTech Health's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -13.488/( (46.872+25.343)/ 2 )
=-1  *  -13.488/36.1075
=37.36 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=34.399 + 12.473
=46.872

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=18.25 + 7.093
=25.343

PureTech Health's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Jun. 2023 )+Total Debt  (Q: Dec. 2023 ))/ count )
=-1  *  -17/( (25.576+25.343)/ 2 )
=-1  *  -17/25.4595
=66.77 %

where

Total Debt  (Q: Jun. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=19.996 + 5.58
=25.576

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=18.25 + 7.093
=25.343

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is two times the semi-annual (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


PureTech Health  (NAS:PRTC) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


PureTech Health Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of PureTech Health's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


PureTech Health (PureTech Health) Business Description

Industry
Traded in Other Exchanges
Address
6 Tide Street, Suite 400, Boston, MA, USA, 02210
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.